Search

Your search keyword '"Shaburishvili T"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Shaburishvili T" Remove constraint Author: "Shaburishvili T"
48 results on '"Shaburishvili T"'

Search Results

4. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

5. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

6. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

7. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

8. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

9. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

10. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy

12. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

14. Saphenous vein graft pseudoaneurysm: Diagnosis by transesophageal echocardiography and magnetic resonance imaging

19. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

21. Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: Rationale, Design and Lead-in Phase Results of the REBALANCE-HF Trial.

22. Serial direct sodium removal in patients with heart failure and diuretic resistance.

23. Early Experience With the Innovalve Transcatheter Mitral Valve Replacement System.

24. Targeted ablation of epicardial ganglionated plexi during cardiac surgery with pulsed field electroporation (NEURAL AF).

25. No-Implant Interatrial Shunt for HFpEF: 6-Month Outcomes From Multicenter Pilot Feasibility Studies.

26. Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR.

27. Synchronized Diaphragmatic Stimulation for Heart Failure With a Reduced Left Ventricular Ejection Fraction Using the VisONE System: A First-in-Patient Study With Extended Population.

28. Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study.

29. Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results.

30. First-in-Human Transseptal Transcatheter Mitral Chordal Repair.

31. Feasibility of a No-Implant Approach to Interatrial Shunts: Preclinical and Early Clinical Studies.

32. Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort.

33. Synchronized diaphragmatic stimulation for heart failure using the VisONE system: a first-in-patient study.

34. ENDO-ACAB EARLY POSTOPERATIVE PERIOD RESULTS: ANALYSIS AND COMPARISON.

35. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

36. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.

37. Spironolactone for heart failure with preserved ejection fraction.

38. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.

39. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.

40. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

41. [Oral spiramycin for prevention of restenosis in coronary arteries].

42. [Comparison between bare metal stents and drug eluting stents for the treatment of chronic total occlusion].

43. [Peculiarities of postprandial activity of lipoprotein lipase in coronary heart disease].

44. [Is always chronic total occlusion indication for recanalization in patients with multi-vessel disease].

45. [Some peculiarities of the activity of postheparin lipoprotein lipase and parameters of lipid metabolism at ischaemic heart disease].

46. [Homocysteine as risk marker of cardiovascular disease].

47. Investigation of cystic left ventricular masses with echocardiography and magnetic resonance imaging.

48. [A method for recording the process of atrial repolarization].

Catalog

Books, media, physical & digital resources